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Effect of Previous Exposure to Malaria on Blood Pressure in Kiliﬁ,
Kenya: A Mendelian Randomization Study
Anthony O. Etyang, MBChB, MMed, MSc, PhD; Sailoki Kapesa, Dip Clin Med & Surg; Emily Odipo, BSc; Evasius Bauni, PhD;
Catherine Kyobutungi, MBChB, MSc, PhD; Marwah Abdalla, MD, MPH; Paul Muntner, PhD; Solomon K. Musani, PhD; Alex Macharia, MSc;
Thomas N. Williams, FMedSci; J. Kennedy Cruickshank, MBChB, MD, FRCP; Liam Smeeth, PhD, FRCGP, FMedSci;
J. Anthony G. Scott, FRCP, FMedSci
Background-—Malaria exposure in childhood may contribute to high blood pressure (BP) in adults. We used sickle cell trait (SCT)
and a+thalassemia, genetic variants conferring partial protection against malaria, as tools to test this hypothesis.
Methods and Results-—Study sites were Kiliﬁ, Kenya, which has malaria transmission, and Nairobi, Kenya, and Jackson, Mississippi,
where there is no malaria transmission. The primary outcome was 24-hour systolic BP. Prevalent hypertension, diagnosed using
European Society of Hypertension thresholdswas a secondary outcome.We performed regression analyses adjusting for age, sex, and
estimated glomerular ﬁltration rate. We studied 1127 participants in Kiliﬁ, 516 in Nairobi, and 651 in Jackson. SCT frequency was 21%
in Kiliﬁ, 16% in Nairobi, and 9% in Jackson. SCT was associated with2.4 (95% CI,4.7 to0.2) mm Hg lower 24-hour systolic BP in
Kiliﬁ but had no effect in Nairobi/Jackson. The effect of SCT in Kiliﬁwas limited to 30- to 59-year-old participants, among whom it was
associated with6.1 mm Hg (CI,10.5 to1.8) lower 24-hour systolic BP. In pooled analysis allowing interaction by site, the effect
of SCT on 24-hour systolic BP in Kiliﬁ was 3.5 mm Hg (CI, 6.9 to 0.1), increasing to 5.2 mm Hg (CI, 9.5 to 0.9) when
replacing estimated glomerular ﬁltration rate with urine albumin to creatinine ratio as a covariate. In Kiliﬁ, the prevalence ratio for
hypertension was 0.86 (CI, 0.76–0.98) for SCT and 0.89 (CI, 0.80–0.99) for a+thalassemia.
Conclusions-—Lifelong malaria protection is associated with lower BP in Kiliﬁ. Conﬁrmation of this ﬁnding at other sites and
elucidating the mechanisms involved may yield new preventive and therapeutic targets. ( J Am Heart Assoc. 2019;8:e011771.
DOI: 10.1161/JAHA.118.011771.)
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• sickle cell disease • sickle cell trait • thalassemia
H igh blood pressure (BP) is a major cause of morbidityand mortality worldwide, and its impact is particularly
substantial in sub-Saharan Africa.1 Examining factors unique
to, or more prevalent in, sub-Saharan Africa might reveal
pathophysiological mechanisms underlying hypertension that
could be exploited to reduce the burden of hypertension.
More than half of Africa’s population lives in areas with
moderate to high malaria transmission.2 Falciparum malaria is
associated with low birth weight, childhood malnutrition, and
chronic inﬂammation, each of which has been associated with
the development of hypertension.3 In addition, children of
women who experienced malaria in pregnancy have higher BP
at 1 year of age than those whose mothers did not have
malaria during pregnancy.4
Mendelian randomization studies, in which genetic poly-
morphisms are used to represent environmental exposures,
are increasingly being applied in determining causality.5 These
natural experiments, based on genes acquired at conception,
overcome the limitations of observational studies while
avoiding the expense and ethical concerns that prevent the
conduct of randomized clinical trials.
Sickle cell trait (SCT) and a+thalassemia are common
genetic polymorphisms among African populations that
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provide protection against malaria. Examining differences in
BP among adults with and without these polymorphisms can
allow inferences to be made as to whether malaria inﬂuences
BP.3 In the present study, we tested whether SCT and
a+thalassemia are associated with lower BP and a lower
prevalence of hypertension in Kiliﬁ, Kenya, where there is
malaria transmission. For comparison, we investigated the
same association in Nairobi, Kenya, and Jackson, Mississippi,
2 areas where there is no malaria transmission.
Methods
Data and Materials Availability
The authors conﬁrm that, for approved reasons, some access
restrictions apply to the data underlying the ﬁndings. The
authors are unable to make the data more freely available
because of the terms for data sharing included in the consent
forms for this study. Data are available through the Data
Governance Committee of the KEMRI Wellcome Trust
Research programme where uses are compatible with the
consent obtained from participants for data collection in this
study. Requests can be sent to the coordinator of the Data
Governance Committee on dgc@kemri-wellcome.org and the
Jackson Heart Study on jhspub@umc.edu.
This Mendelian randomization study was performed among
residents of 3 sites (Figure S1) with different levels of malaria
transmission; Kiliﬁ, Kenya, where there has been moderate
malaria transmission,6–8 and 2 sites (Nairobi, Kenya, and
Jackson, Mississippi) where there is no malaria transmis-
sion.9–11 We utilized SCT, which offers 50% to 90% protection
against malaria episodes,12,13 predominantly in childhood,14
to represent malaria exposure (Figure S2). In a secondary
analysis among Kenyan participants, we used a+thalassemia,
which provides a lower level of protection against malaria
than SCT. To be eligible for the study in Kenya, individuals had
to be 10 years or older at investigation and to be lifelong
residents of Kiliﬁ or Nairobi. In Kiliﬁ, we recruited randomly
selected residents of Chasimba and Junju locations within the
Kiliﬁ Health and Demographic Surveillance System.15 Kiliﬁ
participants were predominantly of the Chonyi subtribe of the
Mijikenda ethnic group. In Nairobi, we recruited randomly
selected residents of the Nairobi Urban Health and Demo-
graphic Surveillance System.16 Study participants in Nairobi
were randomly selected from among those who had self-
identiﬁed as belonging to ethnic groups known to have a high
frequency of malaria-protective polymorphisms (Luhya, Luo,
Teso, Mijikenda).17,18 Data were collected in Kenya between
December 2015 and June 2017. Participants in the United
States were blacks aged 21 years and older recruited into the
Jackson Heart Study between 2000 and 2004.19
We used appropriately sized cuffs on the nondominant arm
to undertake ambulatory BP monitoring (ABPM). We used the
Arteriograph24 (TensioMed Ltd.) device in Kenya and the
Spacelabs 90207 (Spacelabs) device in the United States. For
the primary analyses, we deﬁned completeness of ABPM
recordings using European Society of Hypertension (ESH)
criteria.20 These criteria require ≥20 daytime (9 AM–9 PM) and
≥7 nighttime (1 AM–6 AM) readings.20 The respective time
periods were used to determine mean daytime and nighttime
BP. The mean 24-hour BP was calculated using all available
readings. Prevalent hypertension was diagnosed among
participants 16 years and older who met any of the ESH-
deﬁned thresholds for ABPM hypertension regardless of
whether they were taking antihypertensive medication. The
thresholds used were 24-hour systolic BP (SBP) ≥130 mm Hg
or 24-hour diastolic BP ≥80 mm Hg, daytime SBP
≥135 mm Hg or daytime diastolic BP ≥85 mm Hg, and/or
nighttime SBP ≥120 mm Hg or nighttime diastolic BP
≥70 mm Hg BP.21,22 Detailed study procedures are described
in the supplement.
Statistical Analysis
The primary outcome was the difference in 24-hour SBP by
SCT status. We determined that a sample of 1115 partici-
pants in Kiliﬁ and 1270 participants in Nairobi and Jackson
combined would provide at least 80% statistical power to
detect a 4-mm Hg difference in 24-hour SBP between
participants with and without SCT at each of these sites,
assuming an SCT frequency of 15% in Kiliﬁ and 10% in
Nairobi/Jackson and an SD for 24-hour SBP of 15 mm Hg.
We deﬁned secondary outcomes as the genotype-speciﬁc
Clinical Perspective
What Is New?
• We tested the hypothesis that previous exposure to malaria
is associated with increased blood pressure (BP).
• We compared BP in individuals with and without sickle cell
trait, which protects against malaria, at 3 sites, 1 where
there is ongoing malaria transmission and 2 where there is
no malaria transmission.
• We found that individuals with sickle cell trait had lower BP
than those without sickle cell trait, but this was only in the
area with malaria transmission, indicating that malaria is
associated with high BP.
What Are the Clinical Implications?
• Conﬁrmation of the existence of a link between previous
exposure to malaria and high BP at other sites and
elucidation of the mechanisms involved may help in ﬁnding
new ways to prevent and treat high BP.
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differences in systolic and diastolic components of daytime
and nighttime BP, and hypertension as deﬁned above. A 2-
sided a level of ≤0.05 was taken to indicate statistical
signiﬁcance.
We used v2 test and Student t test to compare categorical
and continuous variables at each site by genotype. Hardy–
Weinberg equilibrium was evaluated using a v2 test. Nonnor-
mally distributed variables were log-transformed before
analysis.
Two types of analyses were conducted to test the
hypothesis. First, we compared BP among participants with
and without SCT at each of the 3 sites, while adjusting for
confounders as described below. Second, we pooled data
from the 3 sites and analyzed whether there was an
interaction in the effect of SCT on BP by site.
In the ﬁrst analyses, which were site-speciﬁc, we per-
formed linear regression to determine whether SCT status
was associated with 24-hour SBP, adjusting for age, sex, and
estimated glomerular ﬁltration rate (eGFR)23 (Figure S3),
which were speciﬁed a priori as potential confounders. These
covariates were also used in Poisson regression models with
robust variance to assess whether SCT was associated with
prevalent hypertension. As a+thalassemia modiﬁes the pro-
tective effect of SCT against malaria,24 we tested for
statistical interaction in their effect under both dominant
and additive conditions among Kiliﬁ participants.
The second, pooled analyses were conducted as follows.
Initially, we tested for heterogeneity in the effect of SCT on BP
in the 2 sites with no malaria transmission, Nairobi and
Jackson, by conducting a linear regression allowing interaction
by site. As there was no evidence of heterogeneity in this
analysis, we combined data from these 2 sites and then
tested whether the effect of SCT on BP differed across sites
with different levels of malaria transmission (Kiliﬁ versus
Nairobi/Jackson). This was conducted in a regression model
that tested for the main effects of age, sex, eGFR, malaria site
(Kiliﬁ versus Nairobi/Jackson) and SCT, and an interaction
term for SCT and malaria site.
Prespeciﬁed subgroup analyses included stratiﬁcation by
age category (10–29, 30–59, and ≥60 years) and sex, and
after exclusion of participants taking antihypertensive
medication. These subgroup analyses were performed for
Kiliﬁ separately and for Nairobi and Jackson combined. We
also examined the effect of replacing eGFR with log-
transformed urine albumin to creatinine ratio as the
covariate representing renal function in the pooled regres-
sion models.
In sensitivity analyses, we repeated the analyses using an
expanded data set that included participants whose ABPM
data met the less stringent IDACO (International Database of
Ambulatory Blood Pressure in relation to Cardiovascular
Outcome) study criteria for completeness. These criteria
require a minimum of 10 daytime (10 AM–8 PM) readings and 5
nighttime (12 AM–6 AM hours) readings.
All analyses were conducted using Stata version 15
software (StataCorp).
The ethical review committees/institutional review boards
of the Kenya Medical Research Institute, London School of
Hygiene and Tropical Medicine, Jackson State University,
Tougaloo College, and the University of Mississippi Medical
Center approved the study. Analysis of Jackson Heart Study
data was approved by the University of Alabama at Birming-
ham’s institutional review board. Written informed consent,
and assent for participants younger than 18 years in Kenya,
was obtained from study participants or parents.
Results
We identiﬁed 9543 lifelong residents in the Kiliﬁ population
register and, using a random number sequence, we invited
2790 to participate in the study (Figure 1). Characteristics of
participants by consent to undergo ABPM and by complete-
ness of ABPM recordings are summarized in Tables S1 and
S2, respectively. Individuals with homozygous sickle cell
disease (n=5) were excluded from all analyses. Complete data
were available for 1127 participants. None of the participants
were previously aware of their genetic status. Overall, 238
(21%) participants had SCT and 768 (67%) were either
heterozygous (a/aa) or homozygous (a/a) for a+tha-
lassemia, equally distributed by SCT status (69% for those
with SCT versus 67% for those without SCT, P=0.5). There was
no departure from Hardy–Weinberg equilibrium for either SCT
(P=0.5) or a+thalassemia (P=0.8). Mean 24-hour SBP was
12718 mm Hg.
Characteristics of participants by study site and SCT status
are presented in Table 1. A higher proportion of participants
without SCT versus participants with SCT in Jackson were
taking antihypertensive medication. In Kiliﬁ, eGFR was lower
among participants with SCT versus participants without SCT.
Urine albumin to creatinine ratio was higher among partici-
pants with SCT versus participants without SCT in Kiliﬁ and
Jackson.
Mean 24-hour SBP in Kiliﬁ was 12618 mm Hg in
individuals with SCT and 12718 mm Hg in individuals
without SCT. In Nairobi/Jackson, mean 24-hour SBP was
12313 mm Hg in individuals with SCT and 123
14 mm Hg in individuals without SCT. After adjusting for
age, sex, and eGFR in regression analyses, SCT was
associated with a 2.4 (95% CI, 4.7 to 0.2) mm Hg
(P=0.037) lower 24-hour SBP in Kiliﬁ (Figure 2). In Nairobi
and Jackson, there was no association between SCT and 24-
hour SBP. As there was no heterogeneity between Nairobi
and Jackson in the effect of SCT on any BP measure (test for
interaction, P=0.409–0.944; Table S3) data from these sites
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were pooled in subsequent analyses. The proportion of
variation in BP explained by the regression model as
determined by the adjusted r2 statistic was 25% in Kiliﬁ,
16% in Nairobi, and 7% in Jackson.
The association between SCT and 24-hour SBP observed in
Kiliﬁ was unaffected by excluding participants taking antihy-
pertensive medication (Table S4).
In Kiliﬁ, SCT was associated with lower 24-hour SBP
(6.1 mm Hg; 95% CI, 10.5 to 1.8 [P=0.006]) among
participants aged 30 to 59 years but not in participants in
the other age categories (Table 2). In Nairobi and Jackson
combined, there was no association between SCT and any
BP measure in any age group except for 24-hour and
daytime diastolic BP in those 60 years and older, where BP
was higher among participants with SCT. In Kiliﬁ, there was
a numerically stronger association between SCT and lower
24-hour SBP in women compared with men but there was
no statistically signiﬁcant interaction by sex (P=0.218,
Table S5).
In the pooled analyses, SCT was associated with
3.5 mm Hg (CI, 6.9 to 0.1) lower 24-hour SBP
(P=0.041) in Kiliﬁ when compared with Nairobi and Jackson
(Figure 3). This interaction model was associated with an
adjusted r2 statistic of 20%. The magnitude of the difference
was larger (5.2 mm Hg; CI, 9.5 to 0.9 [P=0.019]) when
we adjusted for log-transformed urine albumin to creatinine
ratio instead of eGFR (Table S6). Stratiﬁed by sex, the effect of
SCT on 24-hour SBP in Kiliﬁ compared with Nairobi/Jackson
was not stronger in women compared with men (P=0.419,
Table S7).
The prevalence of hypertension among study participants
was 56% in Kiliﬁ, 28% in Nairobi, and 62% in Jackson. In Kiliﬁ,
the adjusted prevalence ratio (PR) for hypertension among
participants with SCT versus those without SCT was 0.86 (CI,
0.76–0.98, P=0.027). In Nairobi and Jackson, the correspond-
ing adjusted PR was 0.96 (CI, 0.80–1.16; P=0.706). When
using clinic BP to deﬁne hypertension (SBP ≥140 and/or
diastolic BP ≥90 mm Hg), the adjusted PR for hypertension
among participants with SCT versus those without SCT in Kiliﬁ
was 0.82 (CI, 0.64–1.05; P=0.113). In Nairobi and Jackson,
the corresponding adjusted PR when using clinic BP was 1.45
(CI, 0.62–3.42; P=0.396).
a+Thalassemia deletions were not associated with the
primary outcome in either Kiliﬁ and Nairobi (Table S8), but a
signiﬁcant association with prevalent hypertension was
present in Kiliﬁ. In Kiliﬁ, the presence of ≥1 thalassemia
deletion was associated with an adjusted PR for hypertension
of 0.89 (CI, 0.80–0.99; P=0.036). There was no effect of
a+thalassemia on hypertension in Nairobi (PR, 1.43; CI, 0.95–
2.15 [P=0.085]).
There was no interaction between a+thalassemia and SCT
on 24-hour SBP in Kiliﬁ (test for interaction, P=0.865).
Lifelong Kilifi residents
(n = 9543)
Lifelong Nairobi residents
(n = 1893)
A Kilifi B Nairobi
Not selected
(n = 6753)
Randomly selected to
participate in the study
(n = 2790)
Randomly selected to
participate in the study
(n = 1327)
Did not attend clinic
(n = 253)
Declined consent
(n = 166)
Attended the clinic
(n = 2537)
Attended the clinic
(n = 1119)
BP data did not meet
quality control criteria
(n 1231)
Consented to
participate
(n = 2371)
Consented to
participate
(n = 1026)
=
Missing samples or
laboratory tests
BP data met quality
control criteria
(n = 1140)
BP data met quality
control criteria
(n = 542)
(n = 13)
Participants with complete
data on BP and covariates
(n = 1127)
Participants with complete
data on BP and covariates
(n = 516)
Jackson Heart
Study participants
C Jackson
Not selected
(n = 566)
Did not volunteer
for the ABPM study
(n = 4158)
(n = 5306)
Did not attend clinic
(n = 208)
Declined consent
(n = 93)
Volunteered for
the ABPM study
(n = 1148)
BP data did not meet
quality control criteria
(n 484)
BP data did not meet
quality control criteria
(n = 214)
BP data met quality
control criteria
=
Missing samples or
laboratory tests
Missing samples or
laboratory tests
(n = 283)
(n = 934)
(n = 26)
Participants with complete
data on BP and covariates
(n = 651)
Figure 1. Study ﬂow chart. ABPM indicates ambulatory blood pressure monitoring; BP, blood pressure.
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Results Based on IDACO ABPM Criteria
The results of sensitivity analyses are presented in Tables S9
through S15. The number of participants who satisﬁed IDACO
criteria for completeness of ABPM data was 2048 (86%). As
expected, the associations between SCT and a+thalassemia
and BP were weaker than in the primary analyses, but the
associations with hypertension remained signiﬁcant. In Kiliﬁ,
SCT was associated with an adjusted PR for hypertension of
0.89 (CI, 0.80–0.99; P=0.025). In Nairobi and Jackson, the
corresponding adjusted PR was 0.96 (CI, 0.81–1.14;
P=0.659). The presence of any a+thalassemia deletion among
individuals in Kiliﬁ was associated with an adjusted PR of
hypertension of 0.92 (CI, 0.84–0.99; P=0.037). In Nairobi, the
corresponding adjusted PR for a+thalassemia was 1.32 (CI,
0.95–1.86 [P=0.096]).
Discussion
In this study, SCT, a genetic polymorphism associated with
partial protection against malaria, was associated with a 2.4-
mm Hg lower mean 24-hour SBP and a 14% lower prevalence
of hypertension in Kiliﬁ, an area with malaria transmission, but
not in Nairobi and Jackson, areas with no malaria transmis-
sion. a-Thalassemia, which provides a lower level of protec-
tion against malaria was associated with an 11% reduction in
the prevalence of hypertension in Kiliﬁ but not in Nairobi. This
suggests that increased risk of malaria is associated with
higher adult BP. In the absence of malaria, in Nairobi and
Jackson, mean BP estimates were marginally higher among
participants with SCT than those without SCT. Incorporating
this baseline observation in a pooled analysis that compared
malaria with nonmalaria sites, we estimate that malaria is
responsible for a mean increase in 24-hour SBP of
3.5 mm Hg.
This difference in BP is roughly similar to those attributed to
reduction of salt intake by 4 g/d25 or a dose of 10 mg/d of
ramipril in the HOPE (Heart Outcomes Prevention Evaluation)
trial.26 At the population level, a reduction in SBP of 3 mm Hg
may avert a substantial number of cardiovascular events
including an 15% reduction in the incidence of stroke.27
However, several factors suggest that the actual effect of
malaria on BP might be greater. First, SCT is only associated
with a 50% reduction in incidence of nonsevere malaria13 and
90% reduction against severe malaria episodes,28 and this
relative protection wanes with age.14 Second, the protection
offered by SCT against malaria is reduced in individuals with
concurrent a+thalassemia,24 who comprised 67% of partici-
pants in the current study who had SCT. The current study was
not powered to analyze the effect of this interaction. In addition,
because Kiliﬁ has low to moderate malaria transmission,6 the
effect of malaria on BP in other parts of Africa where malaria is
endemic could be considerably higher.
Table 1. Characteristics of Study Participants With and Without SCT by Study Site
Characteristic
Kiliﬁ (N=1127) Nairobi (N=516) Jackson (N=651)
SCT (n=238) Non-SCT (n=889) SCT (n=82) Non-SCT (n=434) SCT (n=58) Non-SCT (n=593)
No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
Women 126 (53) 528 (59) 40 (49) 235 (54) 38 (66) 392 (66)
Smoker 17 (7) 78 (9) 3 (4) 7 (2) 5 (9) 74 (12)
Previously diagnosed with hypertension* 37 (16) 127 (14) 7 (9) 53 (12) 31 (53) 367 (62)
Taking antihypertensive medication 9 (4) 26 (3) 0 (0) 8 (2) 26 (46) 338 (61)
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Age, y 41 (22) 39 (22) 20 (14) 23 (18) 61 (12) 60 (11)
BMI, kg/m2 20.6 (3.6) 20.6 (3.8) 20.2 (3.9) 20.5 (4.3) 31.1 (7.0) 30.9 (6.3)
HbA1c, % 5.2 (0.6) 5.1 (0.8) 5.2 (1.1) 5.2 (1.0) 6.0 (1.2) 6.1 (1.3)
Hemoglobin, g/dL 12.6 (2.0) 12.6 (1.6) 13.4 (1.7) 13.2 (1.7) 12.8 (1.4) 13.0 (1.4)
WBC count 9109/L 5.7 (1.5) 5.7 (1.4) 5.4 (1.4) 5.4 (1.6) 4.9 (1.1) 5.3 (1.5)
Platelet count 9109/L 267 (97) 262 (83) 283 (99) 287 (100) 230 (58) 243 (61)
Plasma osmolality, mOsm/kg 290 (6.6) 290 (5.8) 291 (10) 291 (11)  ()  ()
eGFR, mL/min per 1.73 m2 108 (35) 114 (42) 118 (27) 115 (24) 85 (26) 87 (26)
Log UACR, mg/g 1.3 (0.5) 1.2 (0.6) 1.3 (0.7) 1.5 (0.7) 1.06 (0.6) 0.90 (0.5)
Plasma osmolality measurements were not available for Jackson participants. BMI indicates body mass index; eGFR, estimated glomerular ﬁltration rate; HbA1c, glycosylated hemoglobin;
SCT, sickle cell trait; UACR, urine albumin to creatinine ratio; WBC, white blood cell.
*Answered “yes” to the question: Has a doctor or healthcare worker previously told you that you have high blood pressure?
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In this epidemiological study, we were not able to study the
physiological mechanisms by which malaria results in higher
BP. However, there are a number of plausible hypotheses. For
example, hypertension may be the consequence of chronic
inﬂammation in childhood induced by malaria3 and inﬂamma-
tion, itself, has been associated with the development of
hypertension.29 Malaria also causes stunting and malnutrition,
which could inﬂuence BP,3 although anthropometric indices
such as BMI were similar in the groups we studied. The
numerically stronger association that we observed between
SCT and BP in women could be explained by SCT-mediated
protection against malaria in pregnancy.30 Malaria in preg-
nancy has been associated with gestational hypertensive
disorders that place women at risk for chronic hypertension.
CD4+ and CD8+ T-cells, which play a role in responses to
malaria,31 as well as partially explain sex differences in
hypertension,32 could possibly explain the sex differences
that we observed. Theoretically, BP could be modulated by
exposure to antimalarial treatment, but this seems an unlikely
explanation because no commonly used antimalarial drug is Ta
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Figure 2. Effect of sickle cell trait (SCT) on blood pressure by
study site. A, Systolic blood pressure and (B) diastolic blood
pressure. Linear regression models with adjustment for age, sex,
and estimated glomerular ﬁltration rate.
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known to elevate BP over the long term. Elucidating
mechanisms by which malaria leads to higher BP could drive
the design of novel therapies for the prevention or treatment
of hypertension.
We studied populations in Nairobi and Jackson that had not
been exposed to malaria to exclude the possibility that the
lower BP associated with SCT in Kiliﬁ could have been caused
by factors other thanmalaria (illustrated in Figure S4). Although
the study was not powered to detect small changes in BP at
these sites, there was no statistically signiﬁcant difference in
BP by SCT status at these 2 sites and there was no evidence of
heterogeneity by site. Other studies also suggest that SCT does
not inﬂuence BP independently. In a study of 15 975 black
patients, where SCT was associated with an increased risk of
kidney disease, there was no difference in baseline clinic BP,
based on SCT.23 There was no difference in incident hyperten-
sion among participants with or without SCT in an analysis of
1995 black patients followed for 25 years.33 A preliminary
analysis from the present data set, restricted to 11- to 17-year-
old Nairobi residents, showed that SCT and a+thalassemia do
not directly inﬂuence BP.34,35 In addition, large genome-wide
association studies have not reported a statistically signiﬁcant
association between SCT and BP.36–38
To invalidate the interpretation of malaria as the cause of
elevated BP in this study it would be necessary for SCT and
a+thalassemia, or loci in linkage disequilibrium with them, to be
associated with a large reduction in BP. This is highly unlikely
because: (1) none of the loci in the Bantu/Central African
Republic haplotype that is predominant among individuals with
SCT in Kiliﬁ has been associated with BP traits; (2) studies in the
United States show that SCT does not reduce the risk of
hypertension-related outcomes such as stroke, heart failure,
and chronic kidney disease,23,39,40 as would be expected if it
lowered BP; and (3) most genetic polymorphisms inﬂuencing BP
tend to have small effects.36,37
Study Strengths
This study had several strengths. First was the use of ABPM,
considered the reference standard for measuring BP.41 By
performing multiple repeated measurements, ABPM gives more
accurateestimatesofBP.20The largest differenceswereobserved
in theprimary analyses that utilizedmore stringentquality criteria,
which provided for better accuracy in measurement without
introducing a selection bias. In addition, in both the primary and
sensitivity analyses, the largest differences were observed when
comparingnighttimemeasurements,whichare lesssusceptible to
interference by daytime activities. Nocturnal BP indices are also
more predictive of cardiovascular outcomes than daytime or 24-
hour values.20,42,43 Second, the Mendelian randomization
approach that we used is a robust design for elucidating causal
relationships.5 We used genetic variants that are strongly
associated with malaria and showed associations with the
outcomes that were consistent with the different levels of
protection against malaria afforded by each variant. Third, study
participants in Kiliﬁ were of the same ethnicity, minimizing the
possibility that population stratiﬁcation could explain the differ-
ences observed. Fourth, we used prospectively collected health
and demographic surveillance system records15,16 to ascertain
residence in malaria/nonmalaria sites.
Study Limitations
Although Mendelian randomization is a well-established
method for inferring causality, there are some residual
limitations. As we did not have medical record data for the
participants in Kiliﬁ, we could not determine the timing,
number, or severity of malaria episodes required to elevate BP
in adult life. These questions could be investigated using
sequential birth cohort studies that take into account the fact
that there has been a marked reduction in malaria transmis-
sion in Kiliﬁ from the year 2000.7 In addition, replication
studies in other areas with malaria transmission are needed to
conﬁrm the observations we made in Kiliﬁ.
Conclusions
SCT was associated with lower BP and reduced prevalence of
hypertension in Kiliﬁ but not in Nairobi, Kenya, or Jackson,
Mississippi, an observation compatible with a causal associ-
ation between malaria and higher BP. One implication is that
Figure 3. Effect of sickle cell trait on blood pressure (BP) in Kiliﬁ
vs Nairobi and Jackson pooled together. Points (and bars)
represent the difference in BP (and 95% CI), measured in mm Hg,
associated with sickle cell trait (SCT) in Kiliﬁ (a malaria site) vs
Nairobi/Jackson (nonmalaria sites). Estimates were derived as the
interaction term (malaria vs nonmalaria sites) in a linear
regression of BP by SCT status after adjusting for age, sex, and
estimated glomerular ﬁltration rate. DBP indicates diastolic blood
pressure; SBP, systolic blood pressure.
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malaria elimination would lead to health beneﬁts well beyond
those currently described. A second implication is that
elucidating the mechanisms by which malaria leads to an
elevation in BP could yield new preventive strategies for
hypertension and consequent cardiovascular disease.
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 Data S1. 
 
Study Procedures 
a) Study Procedures in Kilifi and Nairobi, Kenya 
Participants were recruited from December 2015 to June 2017. We recruited 
participants aged ≥10 years that were lifelong residents of the Nairobi Urban Health 
and Demographic Surveillance System1 and the Kilifi Health and Demographic 
Surveillance System2 respectively (locations shown in Figure S1). Lifelong residency 
was confirmed using prospectively collected residency data from enumeration 
rounds that are conducted every 3-4 months within the demographic surveillance 
systems. Continuous residency was required in order to minimize misclassification of 
exposure to malaria as Nairobi and Kilifi have markedly contrasting malaria 
transmission patterns. Study participants in Nairobi were randomly selected from 
those who had self-identified as belonging to ethnic groups known to have a high 
frequency of malaria protective polymorphisms (Luhya, Luo, Teso, Mijikenda) as a 
result of hailing from parts of Kenya that are known to be endemic for malaria.3, 4 
Study participants in Kilifi were predominantly from the Chonyi subtribe of the 
Mijikenda community. The prevalence of hypertension within the Kilifi Health and 
Demographic Surveillance System which covers an area of 900km2 is ~17%.5 
However there are significant differences in the incidence to death due to stroke 
within the study area. Chasimba where >75% of study participants came from has an 
incidence of death due to stroke that is three times that of Kilifi township, suggesting 
that there are local geographical differences in the prevalence of hypertension which 
is the main risk factor for stroke.  
In both Kilifi and Nairobi, trained study staff visited all individuals who had been 
selected to participate in the study at their homes and requested them to come to the 
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 study clinic to undergo study procedures. Those who failed to come to the clinic 
within 3 months of being requested to do so were considered to have declined our 
invitation to participate in the study. 
At the clinic participants first underwent an interview where they answered questions 
about their past medical history and their socioeconomic status based on the multi-
dimensional poverty (MDP) index.6 Weight and height were measured using a 
validated SECA 874™ weighing machine and a portable stadiometer (Seca 213™), 
respectively. Body mass index was calculated as the weight in kilograms divided by 
height in meters squared (kg/m2). We did not classify BMI by age-category in the 
adolescents that we studied. Mid-upper arm circumference (MUAC) was measured 
in a standardized manner using TALC™ MUAC tapes. All participants were 
subsequently fitted with a validated Arteriograph24™(TensioMed Ltd., Budapest, 
Hungary)  device for 24-hour ABPM measurement.7 The devices were attached on 
the non-dominant arm and were programmed to take measurements every 20 
minutes during daytime hours (0600-2200 hrs) and every 40 minutes at night (2200-
0600 hrs). At the end of the 24-hour period, participants returned to the study clinic 
where the Arteriograph was removed and data downloaded onto computers that 
would later (within 12 hours) synchronize their data onto an MySQL database hosted 
on servers located at the KEMRI-Wellcome Trust Research Programme offices in 
Kilifi, Kenya. 
We collected 10ml of blood from participants for full blood count, determination of 
sickle hemoglobin status and serum electrolytes. After performing automated full 
blood counts using an ACT 5™ machine, whole blood samples were frozen at -80ºC 
and then transported to the KEMRI-Wellcome Trust Research Programme 
laboratories in Kilifi, Kenya for determination of sickle hemoglobin status. DNA was 
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 extracted retrospectively from the frozen samples by use of Qiagen™ DNA blood 
mini-kits (Qiagen, Crawley, United Kingdom) and typed for sickle hemoglobin and 
+thalassemia using polymerase chain reaction. Glycosylated hemoglobin levels 
were determined using the Biorad™ D-10 machine (Bio-rad Laboratories Inc, 
Hercules, California). 
Serum and urine samples collected from participants were frozen at -80ºC within 4 
hours of collection and later transported to the laboratories in Kilifi for analysis. We 
determined urea and creatinine levels in these samples using ion electrophoresis 
and the jaffe method, respectively.8 Creatinine measurements were performed using 
Isotope dilution mass spectrometry traceable methods. In addition, we determined 
albumin levels in the urine samples by immunoturbidometry using a Quantex™ 
microalbumin kit. Estimated glomerular filtration rate (eGFR) was calculated using 
the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation in 
adults and the Schwartz equation in those aged ≤16 years.9, 10 
b) Study Procedures in Jackson, Mississippi, USA 
The Jackson Heart Study (JHS)11 is a population-based prospective cohort study, 
which was designed to evaluate cardiovascular disease risk among blacks. The JHS 
enrolled 5306 noninstitutionalized blacks, aged ≥21 years, between 2000 and 2004. 
The participants were recruited from the Atherosclerosis Risk in the Community site 
in Jackson, MS, and a representative sample of urban and rural Jackson, MS, 
metropolitan tricounty (Hinds, Madison, and Rankin counties) residents, volunteers, 
randomly selected individuals, and secondary family members.12 The current 
analysis was restricted to JHS participants who completed ABPM soon after the 
baseline study visit (visit 1). 
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 During in-home interviews, trained African American interviewers administered 
standardized questionnaires to collect self-reported information on socio-
demographics (e.g. age, sex, education, marital status and socioeconomic status), 
previously diagnosed co-morbid conditions and selected health-related behaviors 
(e.g. current smoking). Weight and height were measured during a clinic visit. 
At the clinic visit, blood samples were collected for full blood count, genetic studies 
and determination of serum sodium, potassium and creatinine concentrations. 24-
hour urine samples were collected for determination of creatinine and albumin 
concentrations. Full blood counts were performed using the Coulter GenS machine 
(BeckmanCoulter, Hialeah, Florida, USA). DNA was extracted from whole blood 
samples using Puregene reagents (Gentra System, Minneapolis, USA) and genetic 
studies were performed as previously described.12 Biochemical tests were performed 
using a Vitros 950 or 250 Ortho-Clinical Diagnostics analyzer (Raritan, new Jersey, 
USA). Urine albumin was measured on a Dade-Behring BN 11 nephelometer (dade-
Behring, Newark, Delaware, USA). All tests were performed at the University of 
Minnesota laboratory with the exception of hematology tests, which were done at the 
University of Mississippi Medical Center.13 Creatinine measurements were 
performed using Isotope dilution mass spectrometry traceable methods. 
Participants were fitted with an ABPM device (Spacelabs 90207, Spacelabs, 
Redmond, WA) on their non-dominant arm. Ambulatory BP was recorded every 20 
minutes. After 24 hours, the device was removed, and data were downloaded onto a 
computer and processed with Medifacts International’s Medicom software (Rockville, 
MD) 
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 Statistical Methods and Considerations 
a) Reporting format 
While there are no specific guidelines for reporting Mendelian randomization (MR) 
studies, the principles outlined in the Strengthening the Reporting of OBsErvational 
studies (STROBE)14 guidelines as well as the STROBE Extension for Genetic 
Association studies (STREGA)15 were used. Reporting was also guided by the 
review by Boef et al. of the quality of reporting of MR studies.16  
b) Sample size estimation 
The sample size calculation for Kilifi was based on a two-sample t-test comparing 
mean 24-hour systolic blood pressure in those with and without the sickle cell trait 
(SCT). The following assumptions were made: 
- That the prevalence of SCT would be ≥15%17 
- That the standard deviation of 24-hour systolic BP would be ≤15 mm Hg5, 18 
Based on these assumptions we calculated that, for Kilifi, we would need a minimum 
of 1115 participants with complete data in order to detect a statistically significant 4 
mm Hg difference in 24-hour systolic BP with at least 80% statistical power.  
For participants in Nairobi/Jackson we assumed that the combined SCT prevalence 
for the two sites would be ≥ 10%.19 Other assumptions were similar to those for Kilifi. 
Based on these assumptions we calculated that for Nairobi/Jackson, we would need 
minimum of 1270 participants with complete data in order to detect a statistically 
significant 4 mm Hg difference in 24-hour systolic BP with at least 80% statistical 
power.  
We assumed that with these numbers, we would achieve enough power for the 
primary outcome measure, a linear regression to determine the effect of SCT on 24-
hour BP measures, while adjusting for age, sex and estimated glomerular filtration 
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 rate (eGFR). The literature suggests that the major consideration for sample size 
calculations in linear regression models is to ensure that there are at least 2-50 
individuals per variable in the model20, a requirement that would almost certainly be 
achieved if most of the assumptions stated above held true. 
c) Quality control criteria for ABPM data 
There are 2 internationally recognized quality control criteria used for ABPM data, 
which are based on completeness of observations. The International Database of 
Ambulatory blood pressure in relation to Cardiovascular Outcomes (IDACO) study21 
defined ABPM data as acceptable if they include ≥ 10 daytime and ≥ 5 nighttime 
readings, where daytime is defined as 1000-2000 hrs and nighttime as 0000-0600 
hrs.21 The guidelines from the European Society of Hypertension (ESH) are more 
stringent; they require ≥20 daytime and ≥7 nighttime readings where daytime is 
defined as 0900 to 2100 hrs and nighttime as 0100 to 0600 hours.22 It is important to 
note that these criteria were arbitrarily set by experts and were not based on 
outcome studies. As the ESH criteria are more stringent they are likely to lead to a 
greater loss of data and subsequent loss of power and precision. However, in order 
to reduce measurement bias and obtain as accurate an effect size as possible, an a 
priori decision was made to restrict our primary analysis to data that met the ESH 
criteria.  
d) Primary and secondary outcome measures 
The primary outcome measure was estimated using a linear regression model to 
determine the effect of SCT on 24-hour systolic blood pressure, after adjusting for 
age, sex and estimated glomerular filtration rate (eGFR). Blood pressures were 
obtained by ambulatory blood pressure monitoring using the Arteriograph24™ 
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 device.7  Numerous studies have shown that the more accurate measurements 
resulting from repeated inflations and more standardized procedures in ABPM make 
it a much better predictor of cardiovascular events than other BP measurement 
methods.22 The justification for adjusting for age, sex and eGFR is given in the 
section below on confounders and model building. 
Secondary outcome measures were defined as follows: 
a) effect of  +thalassaemia on 24-hour, daytime and nighttime systolic blood 
pressures, after adjusting for age, sex and estimated glomerular filtration rate 
b) effect of SCT on 24-hour, daytime and nighttime diastolic blood pressures, 
after adjusting for age, sex and estimated glomerular filtration rate 
c) effect of  +thalassaemia on 24-hour, daytime and nighttime diastolic blood 
pressures, after adjusting for age, sex and estimated glomerular filtration rate 
d) prevalence ratio for hypertension in those with and without SCT using log-
binomial regression, adjusting for age, sex and estimated glomerular filtration 
rate 
Hypertension was diagnosed by any one of the following criteria in individuals 
aged ≥16 years: 22, 23  
i) 24-hours systolic BP ≥130 mmHg and/or 24-hour diastolic BP ≥ 90 mm 
Hg 
ii) Daytime systolic BP ≥135 mm Hg and/or daytime diastolic BP ≥ 85 mm 
Hg 
iii) Nighttime systolic BP ≥ 120 mm Hg and/or nighttime diastolic BP ≥ 70 
mm Hg 
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 Adjustment for multiple testing was not considered necessary in this scenario of a 
limited number of clinically relevant pre-specified tests (e.g. compared to GWAS 
studies)24 
e) Adjusting for confounders and model building 
The theoretical basis for the malaria-high blood pressure hypothesis has been 
published previously.25 Briefly, the primary hypothesis is that individuals in Kilifi who 
were exposed to more malaria disease in childhood (represented by those having 
haemoglobin AA) would have higher 24-hour systolic blood pressure than those who 
were exposed to less malaria disease (represented by those having haemoglobin AS 
[SCT]). The proposed causal diagram drawn purely for purposes of informing the 
analytical plan can be found in Figure S2. 
 
For purposes of this analysis it is important to note that because malnutrition and 
stunting are on the causal pathway from malaria to the outcome, adjustment for body 
mass index (BMI) and other anthropometric indices (e.g. mid upper arm 
circumference) would be inappropriate. 
 i) Confounders 
The principle of Mendelian randomization holds that because comparisons are 
based on genetic traits acquired at conception, any relationships between the 
genetic trait and the outcome are unlikely to be confounded by other exposures as 
these will be randomly distributed between carriers and non-carriers of the trait.26 
However age, sex, and BMI are known to have a very strong influence on BP and 
other cardiovascular diseases27, and are usually adjusted for as ‘fixed covariates’ in 
MR/Genome wide association studies 28-31. We have outlined above why it would be 
inappropriate to adjust for BMI. 
D
ow
nloaded from
 http://ahajournals.org by on March 27, 2019
  
Sickle cell trait has been associated with impaired kidney function as measured by 
decline in estimated glomerular filtration rate (eGFR) and albuminuria.19 This 
association is independent of blood pressure elevation. Impaired kidney function is 
associated with elevations in blood pressure as a result of sodium retention32, 
increased activity of the renin-angiotensin system33, increased sympathetic activity34, 
secondary hyperparathyroidism35, impaired nitric oxide synthesis36 and increased 
prevalence of nocturnal non-dipping BP pattern.37 It is also possible that kidney 
disease could arise from hypertension.38 The direction of the relationship between 
blood pressure and kidney function, has been the subject of debate.39 However, 
evidence from genetic studies suggests that the association between renal function 
and blood pressure is likely to likely to be explained by decreased renal function 
giving rise to high blood pressure. In a large (n>200,000) genome wide association 
study (GWAS), loci that were associated with blood pressure elevation and 
cardiovascular disease showed no association with kidney disease or kidney 
function.29 If SCT compromises renal function and this in turn leads to elevated blood 
pressure, this would result in a bias toward a null result when using SCT as a proxy 
for testing the malaria-high blood pressure hypothesis. As can be seen in Figure S3, 
impaired kidney function (as measured by eGFR) is associated with both the 
exposure and the outcome, but is not on the causal pathway from malaria to the 
outcome. Kidney function is therefore considered a confounder and we adjusted for 
eGFR in all regression analyses. We also examined the effect of using urine albumin 
to creatinine ratio in place of eGFR in the regression models. 
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 If, however, renal function lies on the causal pathway between malaria and high 
blood pressure it would be inappropriate to include it within the regression models. 
Severe malaria does occasionally present with acute renal failure and repeated 
episodes of malaria could result in chronic pyelonephritis and elevated BP. However, 
acute renal failure is a very rare complication of malaria in Kilifi, for example, it 
occurred in 2 out of 1844 children admitted with malaria.40 This suggests that renal 
failure is an unlikely mediator of the potential association between malaria and 
elevated BP.  
We confirmed that each of the a priori specified covariates (age, sex and eGFR) 
significantly improved the regression models using the likelihood ratio test. 
  Confounding due to pleiotropy 
A special type of confounding can also occur if the genetic trait influences the 
outcome through a pathway that is independent of the exposure (pleiotropy)41 as 
illustrated in Figure S4. 
 
In contrast with renal function, which is a known confounder and can be measured 
and adjusted for in regression analyses, confounding due to other (often unknown) 
causes can only be detected by examining the relationship between sickle cell trait 
and blood pressure in individuals who have not been exposed to malaria. The 
existence of pleiotropy can invalidate the use of the genetic trait as a marker for the 
infectious disease exposure. In order to exclude pleiotropy as a potential explanation 
for the association between SCT and BP, we studied lifelong residents of Nairobi, 
Kenya and Jackson, Mississippi, two sites where there is no malaria transmission.  
In addition, we conducted a pooled analysis incorporating data from the three study 
sites and conducted a linear regression with the previously specified covariates plus 
SCT and study site and their interaction. This increased the power to detect any 
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 independent effect of SCT on BP while simultaneously checking for differential effect 
of SCT according to study site. 
ii) Effect modifier:  +thalassemia  
 +thalassemia, in which there is reduction in the amount of alpha hemoglobin, is 
common in regions where malaria transmission occurs. Williams et al42 have 
demonstrated a negative epistatic effect when +thalassemia is coinherited with 
SCT. The effect of coinheritance of the mutations is to reduce the malaria protective 
effect of SCT to about 27% (from 50%) for uncomplicated malaria and to 44% (from 
80%) for severe malaria.42 Put simply, the presence of  +thalassemia reduces the 
protective effect of SCT against both uncomplicated and severe malaria by about 
half. We therefore included  +thalassemia as an interaction term (interacting with 
SCT) in the main regression model and examined whether its inclusion changed the 
effect estimate for SCT in predicting blood pressure. 
In a related analysis, we ran a linear regression model examining the effect of 
+thalassemia on blood pressure with the same covariates used in the main analysis 
for SCT. Because +thalassemia confers less protection against malaria than SCT, 
we expected that the effect estimate in this model would be lower than that of SCT. 
f) Testing for cohort effects  
Malaria incidence in Kilifi has been changing over time and we considered that this 
could influence results obtained. Data on the changing levels of transmission go 
back to 1990 and they show that a significant drop in transmission in Kilifi began 
around 1999-2000.43 In addition, because blood pressure rises with age, it is 
possible that the effects of malaria on outcome measures may be more apparent 
later in life. While it is not possible to determine the individual contributions of 
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 changing malaria exposure and aging to any differences observed in outcome 
measures, we attempted to display these differences by performing comparisons of 
the outcomes by sickle trait in 3 age strata.  
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Table S1. Characteristics of those who consented to undergo ABPM versus those who declined. 
 
 Kilifi 
 N=2537 
 
 
Nairobi 
N=1119 
 
 
Jackson  
N=5306 
 
  
Consented 
n=2371 
Did not 
consent 
n=166   
Consented 
n=1026 
Did not 
consent 
n=93   
Consented 
n=1148 
Did not consent 
n=4158  
Characteristic  n (%) n (%) p-value  n (%) n (%) p-value  n (%) n (%) p-value 
Female 
 
1361 (54) 84 (51) 0.408  480 (47) 45 (48) 0.443  780 (68) 2591 (62) <0.001 
  mean (SD) mean (SD) p-value  mean (SD) mean (SD) p-value  mean (SD) mean (SD) p-value 
Mean Age, years 
 
39 (22) 48 (22) <0.001  22 (16) 25 (17) 0.073  59 (11) 54 (13) <0.001 
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Table S2. Characteristics of participants with and without good quality ABPM data. 
 
 Kilifi 
 N=2371 
 
 
Nairobi 
N=1026 
 
 
Jackson  
N=1148 
 
  
Met ESH criteria 
n=1140 
Did not meet 
ESH criteria 
n=1231 p-value  
Met ESH 
criteria 
n=542 
Did not meet 
ESH criteria 
n=484 p-value  
Met ESH 
criteria 
n=934 
Did not meet 
ESH criteria 
n=214 p-value 
Characteristic  n (%) n (%)   n (%) n (%)   n (%) n (%)  
Female 
 
660 (58) 520 (48) <0.001  290 (54) 237 (49) 0.300  630 (67) 150 (73) 0.134 
Have sickle cell trait 
 
240 (21) 205 (19) 0.240  83 (15) 50 (14) 0.637  58 (8.9) 10 (7.5) 0.588 
Smoker 
 
96 (8) 87 (8) 0.761  11 (2) 12 (3) 0.198  103 (11) 40 (19) 0.001 
Previously diagnosed  
hypertensive§ 
 
165 (14) 133 (12) 0.140  62 (11) 23 (7) 0.017  560 (60) 122 (59) 0.779 
 On anti-hypertensive 
 medication 
 
36 (3) 16 (1.5) 0.009  9 (2) 3 (1) 0.315  519 (59) 116 (59) 0.930 
  mean (SD) mean (SD) p-value  mean (SD) mean (SD) p-value  mean (SD) mean (SD) p-value 
Age, years 
 
40 (22) 36 (21) <0.001  23 (17) 19 (15)   59 (11) 58 (12) 0.360 
BMI kg/m2 
 
20.6 (3.8) 20.6 (4.0) 0.689  20.4 (4.1) 19.7 (4.0) 0.010  30.9 (6.5) 33.1 (5.8) <0.001 
HbA1c, % 
 
5.1 (0.7) 5.1 (0.6) 0.134  5.3 (0.98) 5.4 (1.2) 0.043  6.0 (1.3) 6.1 (1.4) 0.776 
Hemoglobin, g/dl 
 
12.6 (1.7) 12.9 (1.6) <0.001  13.3 (1.7) 13.4 (1.7) 0.421  13.0 (1.4) 13.0 (1.5) 0.661 
WBC count X109/L 
 
5.7 (1.4) 5.7 (1.6) 0.718  5.4 (1.6) 5.5 (1.4) 0.187  5.3 (1.6) 5.8 (1.9) 0.002 
Platelet count X109/L 
 
264 (86) 257 (81) 0.064  289 (100) 302 (88) 0.046  243 (62) 250 (69) 0.078 
eGFR, ml/min/1.73m2 
 
113 (41) 119 (40) <0.001  116 (25) 119 (24) 0.090  86.6 (25) 87.8 (25) 0.540 
Log UACR, mg/g 
 
1.2 (0.62) 1.2 (0.61) 0.674  1.3 (0.71) 1.40 (0.60) 0.345  0.90 (0.50) 0.90 (0.56) 0.860 
ABPM: Ambulatory blood pressure monitoring; eGFR: Estimated glomerular filtration rate; ESH: European society of hypertension. UACR: urine albumin to creatinine ratio 
ESH criteria require a minimum of 20 valid readings taken between 9 a.m. and 9 p.m. and a minimum of 7 valid readings taken between 1a.m. and 6 a.m.  in order for ABPM 
readings to be considered as complete. 
§Answered “yes” to the question: Has a doctor or healthcare worker previously told you that you have high blood pressure? 
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Table S3. Effect of sickle cell trait on blood pressure in Nairobi and 
Jackson. 
 
 
Nairobi 
 (N=516) 
  
Jackson 
 (N=651) 
 
  
 
  
 
ABPM measure 
 
β (mm Hg) (95% CI) p value   β (mm Hg) (95% CI) p value 
 
p-value for 
interaction 
24 hour SBP 
 
0.6  (–2.5, 3.7) 0.722 
  
0.6 (–3.0, 4.2) 0.732 
 
0.944 
24 hour DBP 
 
0.5  (–1.6, 2.6) 0.652 
  
0.8 (–1.5, 3.1) 0.489 
 
0.695 
Nighttime SBP 
 
0.7  (–2.5, 4.0) 0.669 
  
–0.2 (–4.3, 4.0) 0.938 
 
0.766 
Nighttime DBP 
 
0.6  (–1.7, 2.9) 0.610 
  
0.8 (–1.8, 3.3) 0.558 
 
0.779 
Daytime SBP 
 
–0.1  (–3.4, 3.2) 0.963 
  
1.3 (–2.3, 4.9) 0.486 
 
0.567 
Daytime DBP 
 
0.1  (–2.3, 2.4) 0.951 
  
1.2 (–1.2, 3.6) 0.310 
 
0.409 
Linear regression models adjusted for age, sex and estimated glomerular filtration rate 
SBP: Systolic blood pressure 
DBP: Diastolic blood pressure 
p-value for interaction represents result of regression models testing for difference in effect of 
sickle cell trait on BP in Nairobi versus Jackson
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Table S4. Effects of sickle cell trait on blood pressure: effect of 
excluding participants taking anti-hypertensive medication. 
 
All participants 
 
 
Kilifi 
 (N=1127) 
  
Nairobi and Jackson 
(N=1166)    
ABPM measure β (mm Hg) (95% CI) p value   β (mm Hg) (95% CI) p value 
24 hour SBP –2.4  (–4.7, –0.2) 0.037 
  
0.7 (–1.6, 3.1) 0.542 
24 hour DBP –1.4  (–2.8, 0.1) 0.068 
  
0.1 (–1.5, 1.8) 0.860 
Nighttime SBP –3.2  (–5.7, –0.6) 0.015 
  
0.5 (–2.2, 3.1) 0.727 
Nighttime DBP –1.8  (–3.3, –0.2) 0.026 
  
0.3 (–1.5, 2.0) 0.773 
Daytime SBP –1.9  (–4.2, 0.4) 0.113 
  
0.7 (–1.7, 3.1) 0.566 
Daytime DBP –1.0  (–2.6, 0.6) 0.223 
  
0.1 (–1.6, 1.8) 0.889 
 
Excluding participants on medication 
 
 
Kilifi 
(N=1092) 
 Nairobi and Jackson  
(N=755) 
ABPM 
measure β (mm Hg) (95% CI) p value 
 
β (mm Hg) (95% CI) p value 
24 hour SBP –2.5  (–4.8, –0.2) 0.034 0.2 (–2.5, 2.8) 0.896 
24 hour DBP –1.4  (–2.8, 0.1) 0.067 –0.2 (–2.0, 1.5) 0.787 
Nighttime SBP –3.1  (–5.7, –0.6) 0.017 0.8 (–2.1, 3.6) 0.597 
Nighttime DBP –1.8  (–3.3, –0.2) 0.028 0.1 (–1.8, 2.1) 0.902 
Daytime SBP –2.0  (–4.3, 0.4) 0.096 –0.4 (–3.1, 2.4) 0.802 
Daytime DBP –1.0  (–2.6, 0.6) 0.205 –0.5 (–2.4, 1.5) 0.630 
 
 
Linear regression models adjusted for age, sex and estimated glomerular filtration rate 
SBP: Systolic blood pressure 
DBP: Diastolic blood pressure
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Table S5. Effect of Sickle cell trait on blood pressure by sex and study 
site. 
 
Kilifi 
 
 Women 
 (N=659) 
  Men 
(N=473)      
ABPM measure        β (95% CI) p value          β (95% CI) 
p 
value 
 Interaction  
p-value 
24 hour SBP –3.7  (–7.1, –0.4) 0.028   –0.7  (–3.7, 2.3) 0.645 
 
0.218 
24 hour DBP –1.9  (–2.8, 0.1) 0.079   –0.7  (–2.7, 1.3) 0.493 
 
0.398 
Nighttime SBP –4.3  (–8.0, –0.6) 0.022   –1.6  (–5.1, 1.8) 0.356 
 
0.335 
Nighttime DBP –2.0  (–4.2, 0.1) 0.067   –1.4  (–3.6, 0.8) 0.217 
 
0.661 
Daytime SBP –3.1  (–6.4, 0.2) 0.068   –0.3  (–3.4, 2.9) 0.875 
 
0.284 
Daytime DBP –1.6  (–3.9, 0.6) 0.154   –0.2  (–2.4, 2) 0.867 
 
0.131 
 
Nairobi and Jackson 
 
 
Women 
 (N=705)   
 
Men 
(N=461) 
 
 
ABPM measure        β (95% CI) p value          β (95% CI) p value 
 Interaction  
p-value 
24 hour SBP 0.9 (–2.2, 4) 0.574   0.7 (–2.9, 4.4) 0.700 
 
0.800 
24 hour DBP 1.2 (–0.9, 3.3) 0.272   –0.4 (–2.9, 2.1) 0.737 
 
0.106 
Nighttime SBP 1.2 (–2.3, 4.7) 0.511   –0.2 (–4.2, 3.8) 0.915 
 
0.512 
Nighttime DBP 1.7 (–0.6, 3.9) 0.139   –0.8 (–3.5, 2.0) 0.586 
 
0.046 
Daytime SBP 0.7 (–2.5, 3.9) 0.679   1.0 (–2.8, 4.8) 0.617 
 
0.998 
Daytime DBP 0.8 (–1.4, 3.1) 0.464   –0.1 (–2.7, 2.5) 0.936 
 
0.319 
 
 
Linear regression models adjusted for age, sex and estimated glomerular filtration rate 
SBP: Systolic blood pressure 
DBP: Diastolic blood pressure 
p-value for interaction represents result of regression models testing for difference in effect of 
sickle cell trait on BP in men versus women 
 
 
 
D
ow
nloaded from
 http://ahajournals.org by on March 27, 2019
  
Table S6. Results of interaction analysis comparing effect of sickle cell trait in Kilifi versus Nairobi/Jackson using log 
urine albumin to creatinine ratio as covariate instead of estimated Glomerular Filtration Rate. 
  
All 
 (N=1583)    
Women 
N=958 
 Men 
N=625 
        β (95% CI) p value   β  (95% CI) p value 
 
β  (95% CI) p value 
24 hour SBP –5.2  (–9.5, –0.9) 0.019   –6.7  (–13, –0.6) 0.030 
 
–3.5  (–9.5, 2.5) 0.249 
24 hour DBP –2.9  (–5.7, –0.1) 0.040   –4.6  (–8.5, –0.8) 0.019 
 
–1.0  (–5.0, 3.1) 0.635 
Nighttime SBP –5.5  (–10, –0.7) 0.026   –6.3  (–13, 0.5) 0.067 
 
–4.7  (–12, 2.1) 0.176 
Nighttime DBP –3.6  (–6.6, –0.6) 0.018   –5.1  (–9.1, –1.1) 0.013 
 
–1.7  (–6.2, 2.8) 0.456 
Daytime SBP –4.8  (–9.2, –0.4) 0.032   –6.5  (–13, –0.4) 0.037 
 
–3.2  (–9.5, 3.0) 0.308 
Daytime DBP –2.5  (–5.5, 0.5) 0.106   –4.1  (–8.3, 0.03) 0.052 
 
–0.9  (–5.3,3.4) 0.673 
 
SCT: sickle cell trait 
SBP: Systolic blood pressure 
DBP: Diastolic blood pressure 
Linear regression models tested for interaction in the effect of SCT by site. Other covariates were age, sex and log urine albumin to creatinine ratio 
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Table S7. Results of pooled analysis comparing effect of sickle cell trait 
in Kilifi versus Nairobi/Jackson stratified by sex. 
 
Women 
 (N=1359) 
  
Men 
(N=934)      
ABPM measure        β (95% CI) p value          β (95% CI) 
p 
value 
 Interaction  
p-value 
24 hour SBP –5.0  (–9.7, –0.2) 0.039   –1.9  (–6.6, 2.8) 0.431 
 
0.419 
24 hour DBP –3.2  (–6.2, –0.1) 0.041   –0.3  (–3.5, 2.9) 0.871 
 
0.110 
Nighttime SBP –5.8  (–11, –0.6) 0.030   –1.8  (–7.1, 3.5) 0.506 
 
0.323 
Nighttime DBP –3.9  (–7.1, –0.7) 0.017   –0.5  (–4.0, 3.0) 0.782 
 
0.086 
Daytime SBP –4.1  (–8.9, 0.7) 0.091   –1.8  (–6.7, 3.2) 0.489 
 
0.549 
Daytime DBP –2.5  (–5.8, 0.7) 0.126   –0.2  (–3.6, 3.3) 0.925 
 
0.207 
Estimates were derived separately for each sex as the interaction term (malaria vs non-
malaria sites) in a linear regression of blood pressure by sickle cell trait status after adjusting 
for age and estimated glomerular filtration rate. Interaction p-value is the result of 3-way 
interaction in regression models testing for difference in effect of sickle cell trait on BP in men 
versus women in Kilifi versus Nairobi and Jackson pooled together. DBP: diastolic blood 
pressure; SBP: systolic blood pressure. 
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Table S8. Effect of +thalassemia on ambulatory blood pressure by study site  
 
Kilifi (N=1125). 
 
 No. of –3.7kb + thalassemia deletions  
  One deletion (Heterozygous)  Two deletions (Homozygous)  
ABPM measure β mm Hg (95% CI) p value  β mm Hg (95% CI) p value  
24 hour SBP –0.1  (–2.2, 2.0) 0.921  –1.1 (–3.8, 1.6) 0.434  
24 hour DBP –0.3 (–1.7, 1.0) 0.651  –0.4 (–2.2, 1.3) 0.646  
Nighttime SBP 0.2  (–2.2, 2.6) 0.879  –1.3 (–4.3, 1.8) 0.416  
Nighttime DBP –0.1  (–2.3, 1.4) 0.919  –0.5 (–2.4, 1.4) 0.597  
Daytime SBP –0.2  (–2.3, 2.0) 0.884  –1.0 (–3.7, 1.8) 0.500  
Daytime DBP –0.1  (–1.5, 1.4) 0.930  –0.3 (–2.2, 1.6) 0.765  
 
Nairobi (N=514) 
 No. of –3.7kb + thalassemia deletions  
  One deletion (Heterozygous)  Two deletions (Homozygous)  
ABPM measure β mm Hg (95% CI) p value  β mm Hg (95% CI) p value  
24 hour SBP 1.1  (–1.3, 3.5) 0.373  3.9 (–0.5, 8.2) 0.083  
24 hour DBP 0.6 (–1.0, 2.3) 0.440  2.6 (–0.4, 5.6) 0.086  
Nighttime SBP 1.9  (–0.6,4.4) 0.144  3.3 (–1.3, 7.9) 0.157  
Nighttime DBP 1.8  (0.05, 3.6) 0.044  2.4 (–0.8, 5.6) 0.138  
Daytime SBP 0.04  (–1.8, 2.6) 0.974  2.9 (–1.8, 7.5) 0.223  
Daytime DBP –0.3  (–2.1, 1.5) 0.748  2.2 (–1.0, 5.5) 0.181  
 
SBP: Systolic blood pressure 
DBP: Diastolic blood pressure 
Linear regression models adjusted for age, sex and estimated glomerular filtration rate.  
*No alpha thalassemia data were available for participants from Jackson 
D
ow
nloaded from
 http://ahajournals.org by on March 27, 2019
  
Results of analyses based on data meeting IDACO criteria for completeness 
 
Table S9. Characteristics of study participants with and without sickle cell trait by study site (IDACO Criteria). 
 
  
Kilifi 
 N=2048 
 
Nairobi 
N=835 
 
Jackson  
N=724 
  
SCT 
n=408 
Non-SCT 
n=1640 
 
SCT 
n=121 
Non-SCT 
n=714 
 
SCT 
n=63 
Non-SCT 
n=661 
Characteristic  n (%) n (%)  n (%) n (%)  n (%) n (%) 
Female  203 (50) 884 (54)  59 (49) 369 (52)  41 (65) 439 (66) 
Smoker  34 (8) 134 (8)  5 (4) 17 (2)  9 (14) 83 (13) 
Previously diagnosed hypertensive§  59 (15) 221 (14)  9 (7) 70 (10)  33 (52) 408 (62) 
Taking antihypertensive medication  11 (3) 38 (2)  2 (2) 10 (1)  27 (44) 377 (61) 
  mean (SD) mean (SD)  mean (SD) mean (SD)  mean (SD) mean (SD) 
Age, years  40 (22) 38 (22)  20 (14) 22 (16)  60 (12) 60 (11) 
BMI kg/m2  20.7 (3.8) 20.7 (3.9)  20.2 (4.0) 20.2 (4.1)  31.0 (6.9) 31.1 (6.4) 
HbA1c, %  5.2 (0.6) 5.1 (0.7)  5.4 (1.3) 5.3 (1.0)  6.0 (1.2) 6.1 (1.3) 
Hemoglobin, g/dl  12.7 (1.9) 12.7 (1.6)  13.4 (1.8) 13.3 (1.7)  12.8 (1.4) 13.0 (1.4) 
WBC count X109/L  5.8 (1.5) 6.5 (22.5)  5.4 (1.3) 5.4 (1.5)  4.9 (1.2) 5.3 (1.5) 
Platelet count X109/L  261 (89) 259 (81)  289 (96) 294 (97)  229 (57) 243 (62) 
Plasma osmolality, mosm/Kg  290 (5.8) 290 (6.3)  291 (12) 291 (12)  - - - - 
eGFR, ml/min/1.73m2  111 (39) 116 (40)  117 (27) 116 (24)  84 (27) 87 (26) 
Log UACR, mg/g  1.3 (0.6) 1.2 (0.6)  1.5 (0.7) 1.3 (0.7)  1.1 (0.6) 0.9 (0.5) 
BMI: Body mass index; eGFR: estimated glomerular filtration rate; HbA1c: glycosylated hemoglobin; SCT: Sickle cell trait; SD: standard deviation; UACR: 
urine albumin to creatinine ratio; WBC: white blood cell. Plasma osmolality measurements were not available for Jackson participants. 
§Answered “yes” to the question: Has a doctor or healthcare worker previously told you that you have high blood pressure?  
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Table S10. Effect of sickle cell trait on blood pressure by malaria site 
(IDACO Criteria). 
 
 
Kilifi 
(N=1965) 
 
Nairobi and Jackson 
 (N=1500) 
 
Nairobi/Jacks
on Interaction  
  
 
ABPM 
measure 
 
β 
(mmHg) (95% CI) p value 
 
β  
(mm Hg) (95% CI) p value  
p-value for 
interaction 
24 hour SBP 
 
–1.4 (–3.1, 0.4) 0.128 
 
0.4  (–1.6, 2.5) 0.697 
 
0.557 
24 hour DBP 
 
–0.7 (–1.8, 0.4) 0.226 
 
0.1  (–1.3, 1.5) 0.910 
 
0.394 
Nighttime SBP 
 
–1.6 (–3.5, 0.4) 0.109 
 
–0.4  (–2.6, 1.9) 0.744 
 
0.622 
Nighttime DBP 
 
–0.9 (–2.1, 0.3) 0.146 
 
–0.3  (–1.8, 1.2) 0.685 
 
0.273 
Daytime SBP 
 
–0.9 (–2.7, 0.9) 0.327 
 
0.6  (–1.6, 2.7) 0.602 
 
0.264 
Daytime DBP 
 
–0.6 (–1.8, 0.7) 0.367 
 
0.1  (–1.4, 1.6) 0.858 
 
0.237 
Linear regression models adjusted for age, sex and estimated glomerular filtration rate 
SBP: Systolic blood pressure 
DBP: Diastolic blood pressure 
p-value for interaction represents result of regression models testing for difference in effect of 
sickle cell trait on BP in Nairobi versus Jackson
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Table S11. Age specific effects of sickle cell trait on blood pressure by study site (IDACO Criteria). 
 
Kilifi 
  24 hour blood pressure  Night time blood pressure  Daytime blood pressure 
Age, 
years 
N SBP (95% CI) DBP (95% CI)  SBP (95% CI) DBP (95% CI)  SBP (95% CI) DBP (95% CI) 
10-29 917 –0.7 (–2.5,1.1) 0.2 (–1.0, 1.4)  –0.2 (–2.2,1.7) 0.4 (–0.9, 1.7)  –1.5 (–3.5, 0.6) 0 (–1.4, 1.4) 
30-59 655 –3.0 (–6.3, 0.3) –2.3 (–4.5, –0.1)  –3.8 (–7.5, –0.2) –2.8 (–5.1, 0.5)  –1.5 (–4.8, 1.9) –1.8 (–4.2, 0.5) 
≥60 393 –0.2 (–5.3, 4.9) –0.4 (–3.1, 3.0)  –0.8 (–6.6, 4.9) –0.5 (–3.7, 2.7)  1.0 (–4.0, 6.1) 0.3 (–2.8, 3.6) 
 
Nairobi and Jackson pooled together± 
Age, 
years 
N SBP (95% CI) DBP (95% CI)  SBP (95% CI) DBP (95% CI)  SBP (95% CI) DBP (95% CI) 
10-29 620 –0.5 (–3.0, 1.9) 0 (–1.5. 1.5)  –1.1 (–3.6, 1.4) –0.6 (–2.2, 1.1)  –0.9 (–3.6, 1.8) –0.4 (–2.2, 1.5) 
30-59 451 –0.4 (–4.6, 3.9) –1.2 (–4.0, 1.6)  –0.7 (–5.5, 4.0) –0.6 (–3.7, 2.5)  –0.2 (–4.5, 4.1) –0.9 (–3.9, 2.1) 
≥60 429 3.7 (–1.2, 8.6) 4.0 (0.9, 7.0)  2.0 (–3.5, 7.6) 3.1 (–0.2, 6.4)  5.1 (0.1, 10.0) 4.8 (1.5, 8.0) 
SBP: Systolic blood pressure 
DBP: Diastolic blood pressure 
Results of linear regression models adjusted for age, sex and estimated glomerular filtration rate 
±Participants in Jackson were aged 21 years and older 
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Table S12. Effect of Sickle cell trait on blood pressure by sex and study site (IDACO 
Criteria). 
 
Kilifi 
 
 Women 
 (N=1046) 
  Men 
(N=919)      
ABPM measure        β (95% CI) p value          β (95% CI) p value 
 Interaction  
p-value 
24 hour SBP –1.9  (–4.5, 0.6) 0.141   –0.8  (–3.2, 1.7) 0.537 
 
0.533 
24 hour DBP –0.7  (–2.3, 0.9) 0.396   –0.7  (–2.3, 0.8) 0.362 
 
0.910 
Nighttime SBP –2.0  (–4.9, 0.8) 0.160   –1.1  (–3.7, 1.6) 0.423 
 
0.653 
Nighttime DBP –0.7  (–2.4, 1.0) 0.417   –1.1  (–2.8, 0.6) 0.200 
 
0.825 
Daytime SBP –1.4  (–3.9, 1.2) 0.292   –0.4  (–3.0, 2.2) 0.759 
 
0.612 
Daytime DBP –0.8  (–2.5, 0.9) 0.353   –0.4  (–2.1, 1.4) 0.679 
 
0.620 
 
Nairobi and Jackson 
 
 
Women 
 (N=879)   
 
Men 
(N=621) 
 
 
ABPM measure        β (95% CI) p value          β (95% CI) p value 
 Interaction  
p-value 
24 hour SBP 0.1 (–2.7, 2.8) 0.962   1.0 (–2.1, 4.0) 0.525 
 
0.272 
24 hour DBP 0.7 (–1.1, 2.6) 0.429   –0.3 (–2.3, 1.8) 0.807 
 
0.371 
Nighttime SBP –0.7 (–3.7, 2.4) 0.674   0.1 (–3.1, 3.4) 0.930 
 
0.294 
Nighttime DBP 0.5 (–1.4, 2.5) 0.604   –0.8 (–3.1, 1.4) 0.476 
 
0.393 
Daytime SBP –0.3 (–3.1, 2.6) 0.856   1.8 (–1.4, 5.0) 0.275 
 
0.096 
Daytime DBP 0.2 (–1.8, 2.1) 0.881   0.6 (–1.7, 2.8) 0.612 
 
0.110 
 
Linear regression models adjusted for age, sex and estimated glomerular filtration rate 
SBP: Systolic blood pressure 
DBP: Diastolic blood pressure 
p-value for interaction represents result of regression models testing for difference in effect of sickle 
cell trait on BP in men versus women 
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Table S13. Effects of sickle cell trait on blood pressure: effect of excluding 
participants taking anti-hypertensive medication (IDACO Criteria). 
 
 
Kilifi 
 (N=1918) 
  
Nairobi and Jackson 
(N=1041)    
ABPM measure β (mm Hg) (95% CI) p value   β (mm Hg) (95% CI) p value 
24 hour SBP –1.3  (–3.1, 0.5) 0.157 
  
–0.3 (–2.5, 1.9) 0.790 
24 hour DBP –0.7  (–1.8, 0.5) 0.254 
  
–0.4 (–1.9, 1.1) 0.613 
Nighttime SBP –1.5  (–3.4, 0.5) 0.136 
  
–0.6 (–2.9, 1.8) 0.639 
Nighttime DBP –0.9  (–2.0, 0.3) 0.162 
  
–0.7 (–2.3, 0.8) 0.356 
Daytime SBP –0.9  (–2.7, 1.0) 0.348 
  
–0.4 (–2.8, 2.0) 0.729 
Daytime DBP –0.5  (–1.8, 0.7) 0.382 
  
–0.4 (–2.0, 1.3) 0.678 
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Table S14. Results of interaction analysis comparing effect of sickle cell trait 
in Kilifi versus Nairobi/Jackson (IDACO Criteria). 
 
  
Model 1 
 (N=3465)    
Model 2  
N=2379 
 
        β (95% CI) p value   β  (95% CI) p value 
 
24 hour SBP –2.1  (–5.0, 0.7) 0.146   –3.3  (–7.0, 0.4) 0.078 
 
24 hour DBP –1.0  (–2.9, 0.8) 0.275   –2.3  (–4.7, 0.1) 0.057 
 
Nighttime SBP –1.5  (–4.6, 1.6) 0.339   –3.1  (–7.2, 0.9) 0.133 
 
Nighttime DBP –0.8  (–2.8, 1.1) 0.337   –2.7  (–5.3, –0.2) 0.032 
 
Daytime SBP –1.8  (–4.8, 1.1) 0.225   –3.1  (–6.8, 0.7) 0.112 
 
Daytime DBP –0.9  (–2.9, 1.1) 0.394   –2.0  (–4.6, 0.6) 0.126 
 
 
Estimates were derived as the interaction term (malaria vs non-malaria sites) in a linear regression of blood 
pressure by sickle cell trait status after adjusting for age, sex and renal function. Renal function was represented 
by estimated glomerular filtration rate in model 1 and by log urine albumin to creatinine ratio in model 2.  SBP: 
Systolic blood pressure. DBP: Diastolic blood pressure 
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Table S15. Effect of +thalassemia on ambulatory blood pressure by study site 
(IDACO Criteria).  
 
Kilifi (N=1961) 
 No. of –3.7kb + thalassemia deletions  
  One deletion (Heterozygous)  Two deletions (Homozygous)  
ABPM measure β mm Hg (95% CI) p value  β mm Hg (95% CI) p value  
24 hour SBP –0.4  (–1.9, 1.2) 0.637  –1.9 (–3.9, 0.2) 0.073  
24 hour DBP –0.4 (–1.4, 0.7) 0.480  –0.7 (–2.0, 0.6) 0.286  
Nighttime SBP –0.1  (–1.9, 1.6) 0.879  –1.5 (–3.7, 0.8) 0.203  
Nighttime DBP –0.3  (–1.4, 0.8) 0.605  –0.6 (–2.0, 0.8) 0.397  
Daytime SBP –0.5  (–2.1, 1.2) 0.581  –2.1 (–4.1, 0.1) 0.059  
Daytime DBP –0.1  (–1.2, 1.0) 0.808  –0.7 (–2.1, 0.8) 0.361  
 
Nairobi (N=771) 
 No. of –3.7kb + thalassemia deletions  
  One deletion (Heterozygous)  Two deletions (Homozygous)  
ABPM measure β mm Hg (95% CI) p value  β mm Hg (95% CI) p value  
24 hour SBP 0.7  (–1.3, 2.6) 0.494  1.6 (–2.0, 5.2) 0.390  
24 hour DBP 0.4 (–0.6, 1.6) 0.572  1.4 (––0.9, 3.7) 0.238  
Nighttime SBP 0.9  (–1.1, 3.0) 0.376  1.2 (–2.6, 4.9) 0.376  
Nighttime DBP 1.0  (–0.4, 2.3) 0.164  1.0 (–1.4, 3.5) 0.420  
Daytime SBP 0.1  (–3.7, 4.1) 0.941  0.2 (–3.7, 4.1) 0.923  
Daytime DBP –0.2  (–1.6, 1.3) 0.837  0.5 (–2.2, 3.1) 0.717  
 
SBP: Systolic blood pressure 
DBP: Diastolic blood pressure 
Linear regression models adjusted for age, sex and estimated glomerular filtration rate.  
*No alpha thalassemia data were available for participants from Jackson 
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Figure S1. Study locations. 
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Figure S2. Causal diagram for the malaria high blood pressure hypothesis. 
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Figure S3. Illustrating confounding effect of kidney function (eGFR) in 
individuals with SCT. 
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Figure S4. Illustrating confounding due to pleiotropy. 
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